The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1308 articles
The launch of the Wegovy pill marks a pivotal shift in obesity treatment. With 80% of new users being first-time patients, oral semaglutide is overcoming historical barriers to care.
GLP-1 medications, initially developed for diabetes, are revolutionizing health outcomes, offering remarkable benefits for inflammation, joint pain, and even mental outlook, alongside significant weight loss.
A groundbreaking Stanford study reveals a genetic reason why approximately 10% of individuals don't respond as expected to GLP-1 receptor agonists, impacting treatments for diabetes and weight loss.
Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.
For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.
Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.
A new experimental medication from Karolinska Institute targets muscle metabolism rather than appetite, offering a potential alternative to Ozempic and Wegovy with fewer side effects.
Mayim Bialik, known for her roles in 'Blossom' and 'The Big Bang Theory,' recently detailed her challenging journey with GLP-1 medications, highlighting severe gastrointestinal distress and other debilitating symptoms. Her candid account serves as a crucial reminder about the potential risks and the importance of careful medical supervision when considering these powerful drugs.
New research from Stanford Medicine reveals a potential solution to the muscle loss associated with GLP-1 medications like Ozempic and Wegovy, offering hope for stronger, healthier weight loss.
